Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
No, it’s like historical fact. Thanks though.
“These would be the two SunGen products, with the potential addition of future approved products. And, to that point...”
And to that point, this has already been done with SunGen. Initial agreement followed by an expansion of additional drug products the two companies will collaborate on. The same could certainly happen with Glenmark to market additional drugs as well, precedent has been set.
Nah it isn’t lol lol
No value placed on their cGMP facility? Lol.
“I am definitely in this for the acquisition as well. FDA Perc response will give some insight as to how soon an acquisition might take place. Acquisition is the only way Nasrat will truly be paid for his efforts.”
This. Agreed.
“Completely refutable”, yet zero actual facts provided to do so. Ok. Lmao.
Great example since there are a plethora of companies in a position to acquire a company with a market cap approaching 1 trillion dollars. /s
Certainly when they only use stock price and nothing else. Recipe for disaster. Lmao
Stock price is certainly not the only metric that matters as both investors and traders can attest to. Lol.
Couldn’t be more wrong.
Yep, was gonna say they mentioned contract manufacturing decreasing in importance to Elite. Good DD. Free up man power for these filings and larger drugs coming online soon I suppose?
Looks like it! See how closing goes.
Those are obviously the preferred pieces of news/events. Clearly in pharma, you get revenues, and ideally profits, from selling your drugs. Said drugs can only be sold after being approved. Said approvals can only happen after being filed. So...
Sales and marketing agreements and ANDA filings are the necessary positive precursors to the ultimate positive news.
Actually completely factual but thanks
Indeed. I haven’t tracked percentages but it is overwhelmingly label changes/other vs drug approvals from what I’ve observed.
Oddly enough, Glenmark just received approval from the FDA for a label change on one of their own ANDAs yesterday.
You’re expecting more goodies?
And here I thought a portion of Dianne’s time was spent updating Elite’s website. She doesn’t even do that. Lol.
I agree, 2 pieces of good news in 2 days!
Wrong again!!!
Either a typo or we’re owed another filing PR!
Well if you work in IR, how would you advise Elite to improve on that portion of the company? I’ve wanted them to make changes there for quite awhile.
It was previously listed on the AMEX (which later became the NYSE). They voluntarily delisted the stock to the OTC because of poor management in the early years. Lots of scientists running lots of tests collecting lots of data but seemingly no competent management to push products to the approval stage.
Fast forward about 10 years or so, Nasrat joins in late 2013 and got SequestOx to the point of filing and CRL. They have since reformulated it to address the FDA’s concerns via the latest in vitro and pilot in vivo studies and have further diversified the pipeline with new drug filings and additional Pharma partner companies.
If you don’t believe in the company and think it has what it takes to become a player in the abuse deterrent markets, sell/don’t buy the stock. If you do, buy and hold or trade the swings. Pretty simple.
Except no one can present a single piece of evidence that that has happened with even regular IR Oxy. Ever. LOL!
Didn’t know the CEO approved drugs, thought that was the FDA’s job. Huh.
Interesting. A year ago today (4/4/17), we filed for the 40M undisclosed synthetic ANDA for pain. Assuming no CRL, we may be due for an approval soon. If I remember correctly, Nasrat said the FDA had not requested any further info as of the last con call.
The company hasn’t filed new ANDAs almost every single quarter?
They haven’t gotten positive trial results on the new SequestOx formulation?
Why is the daily price fluctuation tied in any way to the company’s fundamentals, especially when no negative news has come out recently?
Hint: It isn’t.
Oh with the less than 100k volume for today? Thought low volume makes a golden cross irrelevant? But I guess there’s a double standard when it comes to death crosses, eh? Haha. Can’t have it both ways, sorryboutcha!
I want cheap shares too.
No, we do not.
Prove it.
Nasrat Hakim, CEO of Elite. You’ll find quite a few form 4s with his name stamped on them. Takes his yearly salary in shares also. I WONDER why that might be. For him, shares clearly are worth more than the salary in USD.
Haven’t seen this OTCX market maker before, although admittedly haven’t watched the trading as closely in recent weeks/months.
Per month? Maybe, but I’d still estimate more.
I wonder when we’ll see approval of this one? Think we get straight approval or just another CRL and it hasn’t hit yet? Coming up on a year since filing.
Don’t forget about Norco. Another ~700M generic ANDA filed by Elite on or around 12/12/16. :)